 |
|
|
| |
Improved Bone and Renal Safety of Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF): Preliminary Results From 2 Phase 3 Studies in HBeAg-positive and HBeAg-negative Patients with Chronic Hepatitis B
|
| |
| |
Reported by Jules Levin
EASL 2017 April 19-21 Amsterdam Netherlands
Henry LY Chan1, Scott Fung2, Wai Kay Seto3, Edward Gane4, John F Flaherty5,
Jenny C Yang5, Lanjia Lin5, Anuj Gaggar5, G Mani Subramanian5, Wan-Long Chuang6,
Kosh Agarwal7, Harry LA Janssen8,9, Maria Buti10
1The Chinese University of Hong Kong, China; 2Toronto General Hospital, Toronto, Ontario, Canada; 3Queen Mary Hospital, Hong Kong; 4Auckland Clinical Studies, Auckland, New Zealand; 5Gilead Sciences, Inc., Foster City, CA, USA; 6Kaohsiung Medical University Hospital, Kaohsiung, Taiwan; 7King's College Hospital, London, UK; 8Toronto Western Hospital, Toronto, Ontario, Canada; 9Erasmus Medical Center, Rotterdam, Netherlands; 10Vall d'Hebron Hospital, Barcelona, Spain
|
| |
|
|
|
|
|
